Wire · opportunities
Quest to add FDA-cleared Roche Alzheimer's test to portfolio
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Quest Diagnostics will add Roche's FDA-cleared Elecsys pTau217 blood test to its Alzheimer’s disease detection portfolio and launch a new multi-biomarker test in the US, aiming to improve early detection and diagnostic accuracy for Alzheimer's disease with more cost-effective, blood-based testing options.
This Wire brief sits within Fusion42's coverage of Medtech, and 6 sources have reported it between 24 Aug 2026 and 26 Aug 2026.
◆ ◆ The Wire takeaway
You have a new chance to offer cheaper, more accessible Alzheimer's diagnostics as Quest rolls out Roche’s FDA-cleared blood test nationwide. This reduces reliance on expensive scans, opening clinical trial and doctor relationships if your product fits blood-based biomarker testing.
◆ Coverage
6 sources · first reported 24 Aug 2026 · latest 26 Aug 2026
◆ Topics